DB2313 is a potent transcription factorPU.1inhibitor with anapoptosisof 14 nM. DB2313 disrupts the interaction ofPU.1with target gene promoters. DB2313 inducesapoptosisof acute myeloid leukemia (AML) cells, and has anticancer effects^[1].

IC50: 14 nM (PU.1)^[1]

DB2313 treatment leads to a profound decrease in the growth of PU.1 URE^–/–acute myeloid leukemia (AML) cells (IC₅₀of 7.1 μM), while showing little effect on normal hematopoietic cells at similar concentrations. DB2313 treatment leads to a 3.5-fold increase in apoptotic cells in murine PU.1 URE^–/–AML cells. DB2313 also leads to a significant decrease in clonogenicity in the second and third rounds of plating and a complete disruption of clonogenic capacity in the fourth and higher rounds of plating^[1].
In AML cells, DB2313 decreases PU.1 occupancy on E2f1, Junb, and Csf1r promoters^[1].

DB2313 (17 mg/kg; i.p.; three times per week; for 3 weeks) treatment decreases leukemia progression and results in increased survival in mice^[1].

708.83

Solid

C₄₂H₄₁FN₈O₂

2170606-74-1

Room temperature in continental US; may vary elsewhere.

DMSO : 3.7 mg/mL(5.22 mM;ultrasonic and warming and heat to 70℃)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 50%PEG300   50% saline

  Solubility: 5 mg/mL (7.05 mM); Suspended solution; Need ultrasonic